Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
A Young Man with Progressive Language Difficulty and Early-Onset Dementia
JAMA Neurol 73:595-599, Botha, H.,et al, 2016
Non-Alzheimers Dementia 1 Frontotemporal Dementia
Lancet 386:1672-1682, Bang, Jee.,et al, 2015
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Frontotemporal Dementia
BMJ 347:f4827, Warren, J.D.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Association of Parental Dementia With Cognitive and Brain MRI Measures in Middle-Aged Adults
Neurol 73:2071-2078, 2054, Debette,S.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Clinical Syndromes Associated with Posterior Atrophy: Early Age at Onset AD Spectrum
Neurol 73:1571-1578, Migliaccio,R.,et al, 2009
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
Biochemical Markers in Persons With Preclinical Familial Alzheimer Disease
Neurol 71:85-92,78, Ringman,J.M.,et al., 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Mild Cognitive Impairment
Lancet 367:1262-1270, Gauthier,S.,et al, 2006
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Preclinical Alzheimer Disease
Neurol 63:2341-2347, Saxton,J.,et al, 2004
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Incidence and Outcome of Mild Cognitive Impairment in a Population-Based Prospective Cohort
Neurol 59;1594-1599, Larrieu,S.,et al, 2002
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
The Value of Informant Versus Individual's Complaints of Memory Impairment in Early Dementia
Neurol 55:1724-1726, Carr,D.B.,et al, 2000
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Screening for Dementia with the Memory Impairment Screen
Neurol 52:231-238,224, Buschke,H.,et al, 1999
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Mild Cognitive Impairment, Clinical Characterization and Outcome
Arch Neurol 56:303-308, Petersen,R.C.,et al, 1999
Serial Magnetic Resonance Imaging of Cerebral Atrophy in Preclinical Alzheimer's Disease
Lancet 353:2125, Fox,N.C.,et al, 1999
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
High Apolipoprotein E e4 Allele Frequency in Age-Related Memory Decline
Ann Neurol 39:548-551, Blesa,R.,et al, 1996